to target immune systems
Emricasan is an orally available pan-caspase inhibitor that effectively reduces inflammation and disease-driven cell damage and death by a process known as apoptosis. Emricasan has been extensively studied in multiple clinical trials involving over 1000 subjects. Emricasan has been chronically dosed for up to 2 -years in immunosuppressed patients and found to be well tolerated. In preclinical models, Emricasan effectively eradicated MRSA bacterial skin infection by a novel host-mediated mechanism of action.
CTS-2090 is a novel, orally available inhibitor of inflammatory caspases that potently inhibits the production of IL-1 and IL-18, both of which are clinically validated as important therapeutic targets. In preclinical studies, CTS-2090 has been shown to distribute to the colon and is highly effective in models of ulcerative colitis and has the potential to be beneficial in bacterial infections in the gastrointestinal tract such as clostridium difficile.